The hypnozoite reservoir of Plasmodium vivax represents both the greatest obstacle and
opportunity for ultimately eradicating this species. It is silent and cannot be diagnosed until it …

The hypnozoite reservoir of Plasmodium vivax represents both the greatest obstacle and
opportunity for ultimately eradicating this species. It is silent and cannot be diagnosed until it …

Primaquine, an 8-aminoquinoline, is the only medication approved by the World Health
Organization to treat the hypnozoite stage of Plasmodium vivax and P. ovale malaria …

Most of the tens of millions of clinical attacks caused by Plasmodium vivax each year likely
originate from dormant liver forms called hypnozoites. We do not systematically attack that …

The relapsing peculiarity of Plasmodium vivax is one of the prime reasons for sustained
global malaria transmission. Global containment of P. vivax is more challenging and crucial …

Failures of primaquine for the treatment of relapsed Plasmodium vivax malaria is a serious
challenge to malaria elimination in Ethiopia, where P. vivax accounts for up to 40% of …

The human malaria parasite Plasmodium vivax imposes unique challenges to its control and
elimination. Primary among those is the hypnozoite reservoir of infection in endemic …

Background Plasmodium vivax transmission in West Africa, dominant for the Duffy-negative
blood group, has been increasingly recognized from both local residents as well as …

The incidence and range of endemic malaria caused by Plasmodium vivax has expanded
during the past 30 years. This parasite forms hypnozoites in the liver, creating a persistent …

Infection by Plasmodium vivax poses unique challenges for diagnosis and treatment.
Relatively low numbers of parasites in peripheral circulation may be difficult to confirm, and …